Vivo Capital LLC Has $55.73 Million Stock Position in DBV Technologies S.A. $DBVT

Vivo Capital LLC increased its stake in DBV Technologies S.A. (NASDAQ:DBVT) by 8.4% during the first quarter, HoldingsChannel.com reports. The fund owned 2,667,569 shares of the company’s stock after buying an additional 205,943 shares during the period. DBV Technologies makes up approximately 4.6% of Vivo Capital LLC’s holdings, making the stock its 5th biggest position. Vivo Capital LLC’s holdings in DBV Technologies were worth $55,726,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. Allworth Financial LP purchased a new stake in shares of DBV Technologies during the fourth quarter valued at $32,000. Royal Bank of Canada acquired a new stake in DBV Technologies during the 4th quarter worth about $34,000. Truvestments Capital LLC raised its holdings in DBV Technologies by 71.3% during the 4th quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock worth $75,000 after buying an additional 1,620 shares during the period. Persistent Asset Partners Ltd purchased a new stake in DBV Technologies during the fourth quarter valued at about $115,000. Finally, Two Sigma Investments LP purchased a new position in shares of DBV Technologies in the third quarter worth approximately $167,000. 71.74% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Wall Street Zen downgraded shares of DBV Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 4th. HC Wainwright reiterated a “buy” rating on shares of DBV Technologies in a report on Tuesday, June 30th. Citigroup reissued an “outperform” rating on shares of DBV Technologies in a research note on Friday, May 1st. Weiss Ratings cut DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 17th. Finally, Guggenheim reissued a “buy” rating and issued a $51.00 price target on shares of DBV Technologies in a research report on Monday, May 4th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $48.50.

DBV Technologies Trading Up 0.0%

NASDAQ DBVT opened at $13.73 on Friday. DBV Technologies S.A. has a 1-year low of $8.51 and a 1-year high of $26.18. The firm’s fifty day simple moving average is $16.16 and its 200-day simple moving average is $19.21. The company has a market capitalization of $813.25 million, a PE ratio of -3.91 and a beta of -0.95.

DBV Technologies (NASDAQ:DBVT) last issued its earnings results on Thursday, July 16th. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.48). DBV Technologies had a negative net margin of 3,506.53% and a negative return on equity of 119.33%. The firm had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $0.90 million. As a group, analysts predict that DBV Technologies S.A. will post -2.05 EPS for the current year.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.